Figure 1.

Change in glycated hemoglobin (HbA_1c) with insulin degludec/liraglutide (IDegLira), degludec and liraglutide according to (a,b) baseline glycated hemoglobin (HbA_1c), (c,d) baseline body mass index (BMI) and (e,f) age in DUAL I Japan and DUAL II Japan. Points represent the observed mean HbA_1c at baseline and the arrows represent the observed mean HbA_1c at end‐of‐trial. Changes from baseline in HbA_1c were analyzed using an analysis of covariance (ancova) model, which included treatment, pre‐trial diabetes treatment, subgroup (baseline HbA_1c, BMI or age), and interaction between treatment and subgroup as fixed factors. For analysis of change in HbA_1c, baseline HbA1c was included as a covariate. Missing data were imputed using last observation carried forward. From the model, treatment differences with 95% confidence intervals (95% CI) were estimated for each subgroup, and the treatment‐by‐subgroup interaction was tested to assess if the treatment effect was affected by the subgroups. ETD, estimated treatment difference.